TuHURA Biosciences (NASDAQ:HURA – Get Free Report) is anticipated to release its earnings data before the market opens on Wednesday, February 12th. Analysts expect TuHURA Biosciences to post earnings of ($0.11) per share for the quarter.
TuHURA Biosciences Price Performance
HURA stock opened at $4.44 on Tuesday. TuHURA Biosciences has a 52 week low of $2.84 and a 52 week high of $14.60. The company’s fifty day simple moving average is $4.72.
Analyst Upgrades and Downgrades
HURA has been the subject of a number of analyst reports. RODMAN&RENSHAW raised shares of TuHURA Biosciences to a “strong-buy” rating in a report on Thursday, December 19th. Maxim Group assumed coverage on TuHURA Biosciences in a research note on Tuesday, November 5th. They issued a “buy” rating and a $15.00 price objective for the company. Finally, Rodman & Renshaw began coverage on TuHURA Biosciences in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 target price on the stock.
About TuHURA Biosciences
TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
See Also
- Five stocks we like better than TuHURA Biosciences
- Pros And Cons Of Monthly Dividend Stocks
- Merck: 4 No-Brainer Reasons to Buy This Dip
- What does consumer price index measure?
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
